You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 2.5% | 2.8% |
| Div Cover | 1.8 | 2.5 |
| Op Mrgn | 28.5% | 37.9% |
| ROCE | 51.1% |
| Latest | Forecast | |
|---|---|---|
| P/E | 21.9 | 0.0 |
| PEG | 0.1 | 0.3 |
| Price / Revenue | 5.5 | 4.6 |
| Price / Book value | 7.0 |
| Latest | Forecast | |
|---|---|---|
| Revenue | 1.5% | 4.6% |
| PBT | 57.9% | n/a |
| EPS | 172.6% | 1.1% |
| DPS | 6.5% | -2.9% |
| Year Ending | Revenue ($m) |
Pre-tax ($m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2018-12-31 | 42,294.00 | 8,701.00 | $2.34 | 32.2 | 0.2 | 166% | $1.99 | 2.6% |
| 2019-12-31 | 46,840.00 | 11,464.00 | $3.84 | 23.7 | 0.4 | 64% | $2.26 | 2.5% |
| 2020-12-31 | 47,994.00 | 8,791.00 | $1.79 | 45.7 | -0.9 | -53% | $2.48 | 3.0% |
| 2021-12-31 | 48,704.00 | 13,879.00 | $4.88 | 15.7 | 0.1 | 173% | $2.64 | 3.4% |
| Merck & Co. posts stronger-than-expected Q4 numbers, guidance falls short Sharecast News | 02 Feb |
|---|---|
| Moderna Covid vaccine sales top $18bn Sharecast News | 09 Jan |
| FDA gives AstraZeneca extension on cancer drug application Sharecast News | 15 Dec |